Your account is not claimed yet. You can sign up with ORCID to claim your account.

Katherine A Vallis (Katherine Vallis)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 14

Top Venues

Chemical science

International journal of radiation biology

EJNMMI physics

Nature chemistry

Oxford Institute for Radiation Oncology, Oxford University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Oxford Institute for Radiation Oncology, Oxford University Jul 1o 2006

United Kingdom

Principal Investigator :: Oncology

Publications

Ole Tietz, Fernando Cortezon-Tamarit, Rod Chalk, Sarah Able, Katherine A Vallis
Tricyclic cell-penetrating peptides for efficient delivery of functional antibodies into cancer cells. Nature chemistry 14 (3) (2022)
Sheik Saleem Pasha, Amrita Banerjee, Sreejesh Sreedharan, Soumendra Singh, Noufal Kandoth, Katherine A Vallis, Samir Kumar Pal, Sumit Kumar Pramanik, Amitava Das
Ultrasensitive Reagent for Ratiometric Detection and Detoxification of iAs III in Water and Mitochondria. Inorganic chemistry 61 (33) (2022)
Katherine A Vallis, Roger F Martin, Nadia Falzone
9th international symposium on physical, molecular, cellular, and medical aspects of Auger processes: preface. International journal of radiation biology (2022)
Javian C Malcolm, Nadia Falzone, Jennifer E Gains, Matthew D Aldridge, David Mirando, Boon Q Lee, Mark N Gaze, Katherine A Vallis
Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [ 177 Lu]Lu-DOTATATE. EJNMMI physics 9 (1) (2022)
Bas M Bavelaar, Lei Song, Mark R Jackson, Sarah Able, Ole Tietz, Irini Skaripa-Koukelli, Philip A Waghorn, Martin R Gill, Robert C Carlisle, Madalena Tarsounas, Katherine A Vallis
Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides. Molecular pharmaceutics 18 (10) (2021)
Irini Skaripa-Koukelli, David Hauton, John Walsby-Tickle, Eloïse Thomas, Joshua Owen, Abirami Lakshminarayanan, Sarah Able, James McCullagh, Robert C Carlisle, Katherine A Vallis
3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation. Cancer & metabolism 9 (1) (2021)
Farasat Kazmi, Katherine A Vallis, Balamurugan A Vellayappan, Aishwarya Bandla, Duan Yukun, Robert Carlisle
Megavoltage Radiosensitization of Gold Nanoparticles on a Glioblastoma Cancer Cell Line Using a Clinical Platform. International journal of molecular sciences 21 (2) (2020)
Martin R Gill, Michael G Walker, Sarah Able, Ole Tietz, Abirami Lakshminarayanan, Rachel Anderson, Rod Chalk, Afaf H El-Sagheer, Tom Brown, James A Thomas, Katherine A Vallis
An 111In-labelled bis-ruthenium(ii) dipyridophenazine theranostic complex: mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells. Chemical science 11 (33) (2020)
Nur Aininie Yusoh, Sze Wei Leong, Suet Lin Chia, Siti Norain Harun, Mohd Basyaruddin Abdul Rahman, Katherine A Vallis, Martin R Gill, Haslina Ahmad
Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition. ACS chemical biology 15 (2) (2020)
Rajeshwari Tiwari, Prashant S Shinde, Sreejesh Sreedharan, Anik Kumar Dey, Katherine A Vallis, Santosh B Mhaske, Sumit Kumar Pramanik, Amitava Das
Photoactivatable prodrug for simultaneous release of mertansine and CO along with a BODIPY derivative as a luminescent marker in mitochondria: a proof of concept for NIR image-guided cancer therapy. Chemical science 12 (7) (2020)
Daniel Jarrett, Eleanor P J Stride, Katherine A Vallis, Mark J Gooding
Applications and limitations of machine learning in radiation oncology. The British journal of radiology 92 (1100) (2019)
Javian Malcolm, Nadia Falzone, Boon Q Lee, Katherine A Vallis
Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. Cancers 11 (2) (2019)
Martin R Gill, Bas M Bavelaar, Philip A Waghorn, Martin R Gill, Afaf H El-Sagheer, Tom Brown, Madalena Tarsounas, Katherine A Vallis
Radiolabeled Oligonucleotides Targeting the RNA Subunit of Telomerase Inhibit Telomerase and Induce DNA Damage in Telomerase-Positive Cancer Cells. Cancer research 79 (18) (2019)
Martin R Gill, Katherine A Vallis
Transition metal compounds as cancer radiosensitizers. Chemical Society reviews 48 (2) (2018)

Katherine A Vallis.css-eqlu8i{font-size:small;padding-left:4px;} (Katherine Vallis)

Publication Activity (10 Years)

Top Topics

Top Venues

Katherine A Vallis (Katherine Vallis)